Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Methodology
1.3. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview
2.3. Scope Of Study
2.4. Crisis Scenario Analysis
2.4.1. Impact Of Covid-19 On The Europe Alzheimer’S Disease Therapeutics & Diagnostics Market
2.5. Major Market Findings
2.5.1. Growing R&D Investment In The Biomarkers For Early Detection Of Dementia
2.5.2. Increasing Demand For The Personalized Medicines

3. Market Dynamics
3.1. Parent Market Analysis
3.2. Key Drivers
3.2.1. Increase In Alzheimer’S Disease Cases
3.2.2. Advancements In Diagnostic Technologies
3.2.3. Growth In The Number Of Drugs Under Development
3.2.4. Expansion Of The Elderly Population
3.3. Key Restraints
3.3.1. Limited Availability Of Surrogate Markers
3.3.2. Late-Stage Drug Failures
3.3.3. Strict Government Regulations

4. Key Analytics
4.1. Key Market Trends
4.1.1. Advancements In In-Vitro Diagnostic Techniques
4.1.2. Usage Of Computed Tomography In The Diagnostics Of Alzheimer’S Disease
4.2. Porter’S Five Forces Analysis
4.2.1. Buyers Power
4.2.2. Suppliers Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Growth Prospect Mapping
4.3.1. Growth Prospect Mapping For Europe
4.4. Market Maturity Analysis
4.5. Market Concentration Analysis
4.6. Value Chain Analysis
4.6.1. R&D
4.6.2. Raw Material
4.6.3. Manufacturing
4.6.4. Wholesalers/Distributors/Retailers
4.6.5. End-User
4.7. Key Buying Criteria
4.7.1. Price
4.7.2. Efficiency
4.7.3. Safety
4.8. Etymology Of The Europe Alzheimer’S Disease Therapeutics & Diagnostics Market
4.9. Phases And Sternness Of Alzheimer’S Disease

5. Market By Product
5.1. Therapeutics
5.1.1. Cholinesterase Inhibitors
5.1.2. Nmda Receptor Antagonists
5.1.3. Other Therapeutics
5.2. Diagnostics
5.2.1. Brain Imaging
5.2.2. Csf Test For Alzheimer’S Disease
5.2.3. Other Diagnostics

6. Geographical Analysis
6.1. Europe
6.1.1. Market Size & Estimates
6.1.2. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Drivers
6.1.3. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Challenges
6.1.4. Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Regulatory Framework
6.1.5. Key Players In Europe Alzheimer’S Disease Therapeutics & Diagnostics Market
6.1.6. Country Analysis
6.1.6.1. United Kingdom
6.1.6.1.1. United Kingdom Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.2. Germany
6.1.6.2.1. Germany Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.3. France
6.1.6.3.1. France Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.4. Italy
6.1.6.4.1. Italy Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.5. Belgium
6.1.6.5.1. Belgium Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.6. Poland
6.1.6.6.1. Poland Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities
6.1.6.7. Rest Of Europe
6.1.6.7.1. Rest Of Europe Alzheimer’S Disease Therapeutics & Diagnostics Market Size & Opportunities

7. Competitive Landscape
7.1. Key Strategic Developments
7.1.1. Mergers & Acquisitions
7.1.2. Product Launches & Developments
7.1.3. Partnerships & Agreements
7.1.4. Business Expansions & Divestitures
7.2. Company Profiles
7.2.1. Baxter International Inc
7.2.1.1. Company Overview
7.2.1.2. Product List
7.2.1.3. Strengths & Challenges
7.2.2. Allergan Plc (Acquired By Abbvie)
7.2.2.1. Company Overview
7.2.2.2. Product List
7.2.2.3. Strengths & Challenges
7.2.3. Biogen Inc
7.2.3.1. Company Overview
7.2.3.2. Product List
7.2.3.3. Strengths & Challenges
7.2.4. Cognoptix Inc
7.2.4.1. Company Overview
7.2.4.2. Product List
7.2.4.3. Strengths & Challenges
7.2.5. Eli Lilly And Company
7.2.5.1. Company Overview
7.2.5.2. Product List
7.2.5.3. Strengths & Challenges
7.2.6. F Hoffmann-La Roche
7.2.6.1. Company Overview
7.2.6.2. Product List
7.2.6.3. Strengths & Challenges
7.2.7. Lupin Limited
7.2.7.1. Company Overview
7.2.7.2. Products List
7.2.7.3. Strengths & Challenges
7.2.8. Merck & Co Inc
7.2.8.1. Company Overview
7.2.8.2. Product List
7.2.8.3. Strengths & Challenges
7.2.9. Novartis Ag
7.2.9.1. Company Overview
7.2.9.2. Products List
7.2.9.3. Strengths & Challenges
7.2.10. Sun Pharmaceuticals Industries Ltd
7.2.10.1. Company Overview
7.2.10.2. Product List
7.2.10.3. Strengths & Challenges
7.2.11. Pfizer Inc
7.2.11.1. Company Overview
7.2.11.2. Products List
7.2.11.3. Strengths & Challenges
7.2.12. Eisai Co Ltd
7.2.12.1. Company Overview
7.2.12.2. Product List
7.2.12.3. Strengths & Challenges
7.2.13. Johnson & Johnson
7.2.13.1. Company Overview
7.2.13.2. Product List
7.2.13.3. Strengths & Challenges
7.2.14. Ge Healthcare
7.2.14.1. Company Overview
7.2.14.2. Product List
7.2.14.3. Strengths & Challenges



List of Figures

List Of Figures
Figure 1: Key Market Trends
Figure 2: Porter’S Five Forces Analysis
Figure 3: Growth Prospect Mapping For Europe
Figure 4: Market Maturity Analysis
Figure 5: Market Concentration Analysis
Figure 6: Value Chain Analysis
Figure 7: Key Buying Criteria
Figure 8: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Product, In 2023
Figure 9: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Therapeutics, 2024-2032 (In $ Million)
Figure 10: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Therapeutics, In 2023
Figure 11: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Cholinesterase Inhibitors, 2024-2032 (In $ Million)
Figure 12: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Nmda Receptor Antagonists, 2024-2032 (In $ Million)
Figure 13: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Therapeutics, 2024-2032 (In $ Million)
Figure 14: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Diagnostics, 2024-2032 (In $ Million)
Figure 15: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, Growth Potential, By Diagnostics, In 2023
Figure 16: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Brain Imaging, 2024-2032 (In $ Million)
Figure 17: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Csf Test For Alzheimer’S Disease, 2024-2032 (In $ Million)
Figure 18: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, By Other Diagnostics, 2024-2032 (In $ Million)
Figure 19: Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, Country Outlook, 2023 & 2032 (In %)
Figure 20: United Kingdom Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 21: Germany Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 22: France Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 23: Italy Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 24: Belgium Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 25: Poland Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)
Figure 26: Rest Of Europe Alzheimer’S Disease Therapeutics & Diagnostics Market, 2024-2032 (In $ Million)

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 3: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: KEY PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES